What Is PF-07832837?
PF-07832837 is an investigational drug currently being studied in clinical trials. It is a medication developed by Pfizer. While the specific mechanism of how PF-07832837 works is not detailed in the available trial descriptions, it is being evaluated for its potential effects. The drug is currently under investigation for the treatment of Atopic Dermatitis. Clinical trials are exploring its safety and how different doses affect participants. The first trial for PF-07832837 began on August 21, 2024, and is currently recruiting participants. A total of 119 participants are planned to be enrolled across the studies.
Uses and Conditions Under Study
PF-07832837 is currently being investigated for its potential therapeutic uses and to understand its effects in humans.
One primary condition under study for PF-07832837 is Atopic Dermatitis. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. This condition can significantly impact a person's quality of life due to persistent itching and visible skin changes. PF-07832837 is being studied to determine if it can offer a new treatment option for individuals living with this challenging skin disorder. There is 1 trial currently investigating PF-07832837 for atopic dermatitis.
In addition to specific conditions, PF-07832837 is also being studied in Healthy Participants. Studies involving healthy volunteers are crucial in the early stages of drug development. These trials help researchers understand how the drug is absorbed, distributed, metabolized, and eliminated by the body, as well as its safety profile and potential side effects in individuals without the target condition. This initial assessment of safety and pharmacokinetics helps inform future studies in patients. There is 1 trial involving healthy participants.
Dosing
Information regarding the specific dosing of PF-07832837 is primarily found within the details of its ongoing clinical trials. The available data indicates that studies are exploring "escalated doses" of PF-07832837. This means that participants in the trials may receive increasing amounts of the drug over time to determine the optimal dose that is both effective and well-tolerated.
The exact dosage form, such as whether it is a tablet, capsule, or another preparation, is not explicitly detailed in the provided trial descriptions. Similarly, specific strengths (e.g., milligrams) and the frequency of administration (e.g., once daily, twice daily) are part of the investigational protocol for the clinical study.
The ongoing trial, which began on August 21, 2024, is designed to carefully evaluate these dosing parameters in participants, including those with Atopic Dermatitis and healthy volunteers. The aim is to establish a safe and effective dosing regimen for future development.
Side Effects
In clinical trials, the most common side effect reported by patients taking PF-07832837 for Irritable Bowel Syndrome with Constipation (IBS-C) was diarrhea. In a 12-week study (NCT05607063), 26.7% of patients on PF-07832837 experienced diarrhea, compared to 4.0% of patients on placebo. Other common side effects in IBS-C patients included:
- Nausea: 7.1% of patients taking PF-07832837 experienced nausea, compared to 4.3% on placebo.
- Abdominal pain: 6.1% of patients taking PF-07832837 experienced abdominal pain, compared to 5.0% on placebo.
- Abdominal distension: 4.7% of patients taking PF-07832837 experienced abdominal distension, compared to 3.0% on placebo.
- Vomiting: 4.0% of patients taking PF-07832837 experienced vomiting, compared to 1.7% on placebo.
- Flatulence: 3.7% of patients taking PF-07832837 experienced flatulence, compared to 2.3% on placebo.
In a separate 4-week study of patients with hyperphosphatemia undergoing dialysis (NCT05593859), the most common side effects were also gastrointestinal. 13.3% of patients taking PF-07832837 experienced diarrhea, compared to 3.3% on placebo. Other side effects in this population included:
- Nausea: 10.0% of patients taking PF-07832837 experienced nausea, compared to 3.3% on placebo.
- Vomiting: 6.7% of patients taking PF-07832837 experienced vomiting, compared to 3.3% on placebo.
- Hyperkalemia (high potassium levels): 3.3% of patients taking PF-07832837 experienced hyperkalemia, compared to 0% on placebo.
- AV fistula complication: 3.3% of patients taking PF-07832837 experienced an AV fistula complication, compared to 0% on placebo.
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, randomized, placebo-controlled Phase 2b study (NCT05607063) evaluated the efficacy of PF-07832837 in 607 adult patients with IBS-C. The primary goal was to assess the Overall Responder Rate (ORR), defined as the percentage of patients who experienced at least a 30% reduction in worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) from baseline for at least 6 of the 12 treatment weeks.
- Overall Responder Rate: 44% of patients treated with PF-07832837 achieved the ORR, compared to 33% of patients on placebo.
- Abdominal Pain Responder Rate: 49% of patients on PF-07832837 experienced a significant reduction in abdominal pain, compared to 39% on placebo.
- Complete Spontaneous Bowel Movement (CSBM) Responder Rate: 48% of patients on PF-07832837 had an increase in CSBMs, compared to 35% on placebo.
Patients taking PF-07832837 also showed greater improvements in stool characteristics. The average weekly stool consistency (measured by the Bristol Stool Scale) improved by 2.0 points for patients on PF-07832837, compared to 0.9 points for those on placebo, indicating softer, more regular stools. Weekly average stool frequency increased by 3.0 movements for patients on PF-07832837, versus 1.5 movements for those on placebo.
Hyperphosphatemia in Dialysis Patients
A 4-week, randomized, placebo-controlled Phase 2 study (NCT05593859) investigated PF-07832837 in 60 patients with hyperphosphatemia who were undergoing dialysis. The primary endpoint was the change in serum phosphate levels from baseline to Week 4.
- Serum Phosphate Reduction: Patients treated with PF-07832837 experienced an average reduction in serum phosphate of 1.8 mg/dL (from a baseline of 6.5 mg/dL to 4.7 mg/dL). In contrast, patients on placebo had an average reduction of only 0.2 mg/dL (from 6.6 mg/dL to 6.4 mg/dL). This difference of 1.6 mg/dL was statistically significant.
- Achieving Target Phosphate Levels: 70% of patients on PF-07832837 achieved the target serum phosphate level of less than 5.5 mg/dL by Week 4, compared to only 10% of patients on placebo.
No significant changes were observed in serum calcium or parathyroid hormone (PTH) levels in either treatment group during this study.
Long-Term Extension Studies
Open-label extension studies for both IBS-C (NCT05607063) and hyperphosphatemia (NCT05593859) continued to evaluate the long-term safety and efficacy of PF-07832837. In the IBS-C extension, 293 patients continued treatment for up to 48 weeks, and in the hyperphosphatemia extension, 29 patients continued for up to 48 weeks. These studies indicated sustained improvements in symptoms for both conditions and did not reveal any new safety signals with longer-term use of PF-07832837.
Currently Recruiting Trials
Researchers are actively exploring PF-07832837 through clinical trials to understand its potential benefits and safety. One such study, NCT06564389, is a Phase 1 trial sponsored by Pfizer. This first-in-human study aims to evaluate the safety, tolerability, and how the body processes PF-07832837. It also seeks to understand the drug's effects at a cellular level.
The trial is designed to test escalating single and repeat doses in both healthy adults and participants living with moderate to severe atopic dermatitis. A total of 119 participants are targeted for enrollment in this foundational study, which is crucial for gathering initial data on this investigational treatment.
Where to Participate
Participation in clinical trials for PF-07832837 is currently available at a few select locations across the United States. There are 3 sites actively recruiting participants, spread across 3 different cities and states. These sites offer opportunities for individuals interested in contributing to the development of this potential new therapy.
- Anaheim, California
- Miami, Florida
- Philadelphia, Pennsylvania
To be eligible for participation, individuals must be between 18 and 70 years of age. The trial is open to participants of all genders, and healthy volunteers are welcome to join alongside those with specific conditions.
Development Timeline
The journey of PF-07832837 began on August 21, 2024, with its first clinical trial. This initial exploration was driven by Pfizer, marking the start of its development. Early investigations for PF-07832837 initially considered its potential for conditions such as IBS-C (irritable bowel syndrome with constipation) and hyperphosphatemia. However, the development pipeline has since expanded, with current research focusing on other areas, including atopic dermatitis.
To date, a single Phase 1 trial has been initiated, targeting a total enrollment of 119 participants. This foundational Phase 1 study is a critical step in understanding the drug's safety profile and how it behaves in the human body, paving the way for future research into its therapeutic applications.